Safe and effective vaccines for the novel coronavirus seem to be like buses: after a long, anxious period of waiting, finally three come along at once.
On Monday, British drugmaker AstraZeneca (LSE: AZN) added positive high-level data for its candidate, AZD1222, to a growing list of encouraging clinical results - following first Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX), and then Moderna (Nasdaq: MRNA).
One dosing regimen showed vaccine efficacy of 90%, while another showed 62%, yielding an average result of 70%. Safety data were also highly encouraging.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze